Get started

Financials · KIDS

OrthoPediatrics Corp. (KIDS) financials

For the twelve months ended Sep 30, 2026, OrthoPediatrics Corp. reported $264.14M of revenue and -$33.88M of net income.

Revenue, TTM
$264.14M
Revenue growth, YoY
+16.1%
Net income, TTM
-$33.88M
Net margin
-12.8%
Free cash flow, TTM
$3.18M
EPS, diluted, TTM
-$1.43
Cash
$17.14M
Total debt
$101.13M
P/S
3.14
Market cap
$829.3M
Annual revenue$236.35M
FY2016FY2025
Annual net income-$39.65M
FY2016FY2025
Annual free cash flow-$15.96M
FY2016FY2025

KIDS revenue and earnings growth

KIDS revenueQ3 2026$72.66M

Quarter YoY
+18.6%
QoQ
+3.1%
FY YoY
+15.4%
5Y CAGR
+27.2%
10Y CAGR
+22.5%

KIDS revenue was $72.66M in fiscal Q3 2026 (ended Sep 30, 2026), up 18.6% from a year earlier and up 3.1% from the prior quarter. For the full fiscal 2025 it was $236.35M, up 15.4% from fiscal 2024. Compound annual growth was +27.2% over 5 years and +22.5% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 11 fiscal years on file.

KIDS net incomeQ3 2026-$5.93M

KIDS net income was -$5.93M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$11.77M a year earlier. For the full fiscal 2025 it was -$39.65M, compared with -$37.82M in fiscal 2024.

KIDS EPSQ3 2026-$0.25

KIDS diluted EPS was -$0.25 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.50 a year earlier. For the full fiscal 2025 it was -$1.69, compared with -$1.64 in fiscal 2024.

KIDS free cash flowQ3 2026$1.59M

KIDS free cash flow was $1.59M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$3.42M a year earlier. For the full fiscal 2025 it was -$15.96M, compared with -$41.31M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$236.35M$204.73M$148.73M$122.29M$98.05M$71.08M$72.55M$57.56M$45.62M$37.30M
Cost of revenue$63.69M$56.13M$37.48M$31.63M$24.65M$16.05M$17.93M$14.88M$11.17M$10.93M
Gross profit$172.66M$148.60M$111.25M$90.66M$73.40M$55.03M$54.62M$42.68M$34.45M$26.37M
Research and development$9.10M$11.03M$10.89M$8.45M$5.54M$5.27M$5.75M$4.73M$3.42M$2.22M
Selling, general and admin$119.83M$102.79M$73.30M$57.90M$46.06M$38.32M$26.66M$20.94M$16.97M$11.63M
Operating income-$39.24M-$35.01M-$26.75M-$25.40M-$18.02M-$26.75M-$9.08M-$9.55M-$6.47M-$6.13M
Interest expense$6.00M$2.62M-$198.0K$2.42M-$3.41M$3.54M$2.25M$2.49M$1.48M
Pre-tax income-$39.19M-$41.93M-$21.31M-$3.69M-$17.39M-$33.67M-$12.69M-$12.03M-$8.95M-
Income tax$460.0K-$4.11M-$338.0K-$4.95M-$1.13M-$723.0K$0$0$0$0
Net income-$39.65M-$37.82M-$20.97M$1.26M-$16.26M-$32.94M-$13.73M-$12.03M-$8.93M-$6.57M
EPS, basic-$1.69-$1.64-$0.92$0.06-$0.84-$1.82-$0.94-$0.96-$5.86-$7.14
EPS, diluted-$1.69-$1.64-$0.92$0.06-$0.84-$1.82-$0.94-$0.96-$5.86-$7.14
Diluted shares23.5M23.1M22.7M20.9M19.3M18.1M14.6M12.6M4.0M1.7M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$19.56M$45.78M$33.03M$10.46M$9.01M$30.13M$72.03M$60.69M$42.58M$1.61M
Short-term investments$41.30M$25.01M$49.25M$109.30M$45.90M$55.14M$0---
Receivables$53.84M$42.36M$34.62M$24.80M$17.94M$17.21M$16.00M$9.00M$5.60M$4.10M
Inventory$133.79M$117.00M$105.85M$78.19M$57.57M$52.99M$38.00M$25.71M--
Current assets$256.42M$237.17M$226.50M$226.72M$133.65M$158.43M$128.06M$97.16M$69.56M$20.83M
Goodwill$109.27M$93.84M$83.70M$86.82M$72.35M$70.51M$13.77M$0--
Total assets$508.63M$473.21M$438.75M$427.73M$304.27M$320.41M$182.15M$112.11M$82.30M$30.68M
Current liabilities$46.20M$33.96M$41.67M$30.87M$29.71M$35.03M$13.66M$9.22M$9.47M$7.25M
Short-term debt$1.87M$897.0K$152.0K$144.0K$137.0K$131.0K$124.0K$118.0K$113.0K$107.0K
Long-term debt$99.82M$72.96M$9.91M$763.0K$907.0K$1.04M$26.07M$21.16M$25.34M$17.43M
Total debt$101.68M$73.85M$10.06M$907.0K$1.04M$1.18M$26.19M$21.27M$25.45M$17.54M
Total liabilities$162.03M$118.64M$61.72M$49.08M$78.91M$85.64M$39.79M$30.37M$34.81M$24.68M
Shareholders' equity$346.60M$354.57M$377.02M$378.65M$225.37M$234.77M$142.36M$81.73M$47.49M-$65.31M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$4.85M-$27.05M-$27.05M-$21.77M-$13.06M-$18.53M-$17.77M-$15.58M-$7.22M-$1.12M
Capital expenditures$11.11M$14.26M$16.88M$10.03M$8.10M$10.50M$11.82M$5.25M$5.21M$4.35M
Free cash flow-$15.96M-$41.31M-$43.92M-$31.80M-$21.17M-$29.03M-$29.59M-$20.84M-$12.42M-$5.47M
Investing cash flow-$43.63M-$13.16M$41.68M-$113.37M-$7.41M-$69.69M-$61.92M-$5.96M-$6.54M-$4.75M
Financing cash flow$23.98M$53.13M$7.30M$135.97M$6.0K$46.73M$91.02M$39.66M$54.73M$3.60M
Dividends paid------$0$0$5.96M$0
Stock-based compensation$17.78M$13.55M$10.53M$6.68M$5.84M$6.20M$2.60M$3.19M$3.48M$1.25M
Depreciation and amortization$21.12M$19.08M$17.39M$13.10M$10.68M$8.01M$4.67M$2.89M$2.40M$1.90M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY15.4%37.6%21.6%24.7%37.9%-2.0%26.0%26.2%22.3%20.3%
Gross margin73.1%72.6%74.8%74.1%74.9%77.4%75.3%74.2%75.5%70.7%
Operating margin-16.6%-17.1%-18.0%-20.8%-18.4%-37.6%-12.5%-16.6%-14.2%-16.4%
Net margin-16.8%-18.5%-14.1%1.0%-16.6%-46.3%-18.9%-20.9%-19.6%-17.6%
Free cash flow margin-6.8%-20.2%-29.5%-26.0%-21.6%-40.8%-40.8%-36.2%-27.2%-14.7%
Return on equity-11.4%-10.7%-5.6%0.3%-7.2%-14.0%-9.6%-14.7%-18.8%-
Return on assets-7.8%-8.0%-4.8%0.3%-5.3%-10.3%-7.5%-10.7%-10.9%-21.4%
Current ratio5.556.985.447.344.504.529.3710.547.352.87
Debt to equity0.290.210.030.000.000.010.180.260.54-

Source: XBRL data OrthoPediatrics Corp. files with the SEC, latest filing dated Oct 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

KIDS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
KIDS$264.14M+16.1%-$33.88M-12.8%$829.3M
SYK$26.30B+7.9%$3.62B13.8%$124.05B
MMM$25.25B+1.7%$3.54B14.0%$95.67B
BSX$21.07B+8.9%$3.50B16.6%$61.96B
BDX$23.25B+17.4%$941.00M4.0%$57.71B
MDLN$30.68B-$683.00M2.2%$52.13B
RMD$5.73B+9.0%$1.59B27.8%$33.10B
DXCM$5.10B+13.0%$991.00M19.4%$29.62B
WST$3.40B+12.6%$638.90M18.8%$27.85B

KIDS FAQ

9 questions
  • What is KIDS revenue?
    OrthoPediatrics Corp. (KIDS) reported $264.14M of revenue for the twelve months ended Sep 30, 2026. That is up 16.1% from the year before. Revenue for fiscal 2025 was $236.35M.
  • Is KIDS profitable?
    No. OrthoPediatrics Corp. reported a net loss of $33.88M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does KIDS have?
    OrthoPediatrics Corp. reported $17.14M in cash and cash equivalents and $101.13M of debt on its most recent balance sheet in SEC filings.
  • How fast is KIDS revenue growing?
    OrthoPediatrics Corp.'s revenue changed +15.4% in fiscal 2025, to $236.35M. Its compound annual growth rate was +27.2% over 5 years and +22.5% over 10 years.
  • What is KIDS gross margin?
    OrthoPediatrics Corp.'s gross profit was $194.84M on $264.14M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 73.8%.
  • What is KIDS free cash flow?
    OrthoPediatrics Corp. generated $3.18M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $12.49M less capital expenditures.
  • What is KIDS earnings per share?
    Diluted earnings per share were -$1.43 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did KIDS last report financial results?
    The latest statements here come from OrthoPediatrics Corp.'s 10-Q filed on Oct 28, 2026, covering the period ended Sep 30, 2026.
  • Where does this KIDS financial data come from?
    Quantisnow builds these statements from the structured XBRL data OrthoPediatrics Corp. files with the SEC. It is provided for information only and is not investment advice.